Imagine dedicating years to battling obesity, only to have the one thing that finally worked—a life-changing medication—ripped away because of insurance decisions. This is the harsh reality for thousands of people in Massachusetts who rely on GLP-1 weight-loss drugs.
For many, like Tierno, these medications aren’t just about shedding pounds; they’re about reclaiming health. Tierno, who had struggled with weight-related issues like high blood pressure and prediabetic blood sugar levels, found relief with Zepbound. “It wasn’t about willpower,” he emphasized. “It was chemical. This drug gave my body the biological support it needed to overcome years of weight gain.”
But here’s where it gets controversial: more than 40,000 customers of Massachusetts’ two largest insurers, Blue Cross and Point32Health, have lost coverage for GLP-1s this year. This number is set to grow, thanks to a recent vote by the Group Insurance Commission, which provides insurance to over 460,000 state employees, retirees, and their families. Even MassHealth, the state’s Medicaid program, might follow suit. In 2024 alone, about 140,400 patients with obesity in Massachusetts were prescribed these medications, which include brands like Zepbound, Wegovy, Ozempic, and Mounjaro.
And this is the part most people miss: the end of insurance coverage doesn’t just mean higher out-of-pocket costs—it means some patients are forced to choose between their health and their finances. Take Michelle Markert, a 55-year-old interior designer from Newton, who lost 35 pounds on GLP-1s. Under her previous plan with Harvard Pilgrim Health Care (owned by Point32Health), her monthly prescription cost $80. Now, after switching to Blue Cross, she faces a $500 monthly bill—equivalent to a car payment. “That extra $420 has to come from somewhere,” she said. “I’ll think twice about going out to eat or even to the movies.”
Blue Cross has notified 25,670 members that they no longer qualify for GLP-1s for obesity, while Point32Health has informed over 15,000 members of the same. Both insurers still cover GLP-1s for diabetes, but for those using them for weight loss, the financial burden is crushing.
Is this fair? Insurers argue that pharmaceutical giants Eli Lilly and Novo Nordisk are to blame, charging exorbitant prices for these drugs. For example, Zepbound and Wegovy can cost between $900 and over $1,300 per month. Blue Cross spent $515 million on GLP-1s in 2025, up from $140 million in 2023, and projected costs were nearing $1 billion this year before coverage restrictions were implemented. Point32Health faced similar challenges, leading both companies to lay off hundreds of employees last year.
But here’s the counterpoint: while insurers point fingers at drug companies, patients are left in the lurch. Dr. Paul Copeland, an endocrinologist and obesity specialist at Massachusetts General Hospital, warns of the dangers. “Pulling these medications from patients doesn’t just lead to rapid weight regain,” he said. “It also worsens comorbidities like cardiovascular risk factors.” A recent study projected that patients who stop taking GLP-1s could regain their lost weight within 18 months.
Direct-to-consumer programs like NovoCare and LillyDirect offer alternatives, with prices ranging from $149 to $449 per month. But as Copeland notes, this creates a two-tier system, favoring those who can afford it. “What about the patients who can’t?” he asks.
Novo Nordisk recently announced plans to cut GLP-1 list prices by up to half in 2027, acknowledging the calls for affordability. But Eli Lilly has shown no such willingness, leaving patients like Robert Atterbury in a bind. Atterbury, a 60-year-old audiology office coordinator from Dorchester, lost 20 pounds on GLP-1s but can’t afford the $299 monthly cost through LillyDirect. “The drug company and the insurer made this decision for me,” he said. “I had no say, except that I can’t afford it.”
Susan Elsbree, a 55-year-old public relations executive from Jamaica Plain, is equally frustrated. After losing 35 pounds, lowering her blood pressure, and eliminating the need for cortisone shots for her arthritic knees, she’s now paying $199 a month to continue Zepbound through a telehealth platform. “This isn’t just about health,” she said. “It’s about equity. The gap between the haves and have-nots is widening.”
So, what’s the solution? Should drug companies lower prices? Should insurers prioritize patient health over profits? Or is there a middle ground? Let us know your thoughts in the comments—this is a conversation that needs to happen.
